Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

NCT01522443 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT01522443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01522443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Lead sponsor
Exelixis
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2012
Completion date
January 13, 2015
Enrollment
119 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostate cancer, pain, prostate cancer, prostatic neoplasms